erlotinib has been researched along with pd168393 in 3 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (pd168393) | Trials (pd168393) | Recent Studies (post-2010) (pd168393) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 61 | 0 | 33 |
| Protein | Taxonomy | erlotinib (IC50) | pd168393 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 1.0702 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0143 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0334 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.1543 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.073 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0011 | |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | 5.47 | |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.5757 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 3.14 | |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | 5.83 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0047 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grütter, C; Klüter, S; Michalczyk, A; Rabiller, M; Rauh, D; Rode, HB; Simard, JR | 1 |
| Balk, SP; Didonato, M; Flatauer, L; Gray, NS; Hur, W; Jiang, X; Kim, S; Larson, B; Mason, DE; Nagle, A; Peters, EC; Suzuki, M; Valente, D; Velentza, A; Warmuth, M; Zagorska, A; Zhang, J | 1 |
| Heynck, S; Pawar, VG; Rabiller, M; Rauh, D; Rode, HB; Sos, ML; Thomas, RK; van Otterlo, WA | 1 |
3 other study(ies) available for erlotinib and pd168393
| Article | Year |
|---|---|
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Topics: Crystallography, X-Ray; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2008 |
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Topics: Animals; Cysteine; ErbB Receptors; Mice; Molecular Structure; Morpholines; Protein-Tyrosine Kinases; Quinazolines; Sequence Homology, Amino Acid | 2008 |
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2010 |